Abstract
This prospective observational study aimed to evaluate the prognostic value of the modified Glasgow prognostic score (mGPS), an inflammation- and nutrition-based index, in patients with non-small cell lung cancer (NSCLC) undergoing radiotherapy (RT) delivered with definitive-dose intent. Adults (≥ 18 years) with histologically or clinically confirmed NSCLC and Eastern Cooperative Oncology Group performance status 0–1 were enrolled. Pretreatment mGPS, derived from serum C-reactive protein (CRP) and albumin levels, was categorized as low (0) or high (1–2). Patients with stage 0–I disease received stereotactic body radiotherapy (SBRT), whereas those with stage II or higher underwent concurrent chemoradiotherapy or definitive RT alone. The primary endpoint was 2-year overall survival (OS); secondary endpoints were 2-year local control rate (LCR) and distant failure-free rate (DFFR). Between January 2021 and March 2023, 82 patients were analyzed (median age, 78 years; 70% treated with SBRT). With a median follow-up of 30.2 months (IQR 23.1–36.3), 2-year OS, LCR, and DFFR were 85.4%, 86.5%, and 80.1%, respectively. High mGPS was significantly associated with inferior OS (hazard ratio [HR] 5.71; 95% CI 1.96–16.66; p = 0.001), but not with LCR or DFFR. In the SBRT subgroup (n = 57), high mGPS remained a strong predictor of inferior OS (HR 7.15; 95% CI 1.73–29.61; p = 0.007). On multivariable analysis, high mGPS persisted as an independent prognostic factor in both the overall and SBRT cohorts. To our knowledge, this is the first prospective study to evaluate mGPS in NSCLC patients treated with RT, including SBRT. High mGPS independently predicted inferior OS in Cox regression analyses, highlighting the prognostic significance of host-related systemic inflammation and nutritional status. These findings support incorporating mGPS into pretreatment evaluation as a simple, objective biomarker to facilitate risk-adapted management and multidisciplinary decision-making in clinical practice.
Similar content being viewed by others
Data availability
The data that support the findings of this study are not publicly available due to patient privacy and ethical restrictions and are available from the corresponding author on reasonable request.
Refferences
Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. Cancer J. Clin. 75, 10–45 (2025).
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. (2024). https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
Vinod, S. K. & Hau, E. Radiotherapy treatment for lung cancer: Current status and future directions. Respirology 25 (Suppl 2), 61–71 (2020).
Ettinger, D. S. et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc Netw. 15, 504–535 (2017).
Tandberg, D. J., Tong, B. C., Ackerson, B. G. & Kelsey, C. R. Surgery versus stereotactic body radiation therapy for stage I non–small cell lung cancer: A comprehensive review. Cancer 124, 667–678 (2018).
Videtic, G. M. et al. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. Int. J. Radiat. Oncol. Biol. Phys. 103, 1077–1084 (2019).
Wang, L. et al. Long-term survival and failure patterns in inoperable early-stage non-small cell lung cancer following stereotactic body radiotherapy: a single-institution retrospective study. Sci. Rep. 14, 30076 (2024).
Antonia, S. J. et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. N. Engl. J. Med. 377, 1919–1929 (2017).
Antonia, S. J. et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N. Engl. J. Med. 379, 2342–2350 (2018).
Spigel, D. R. et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. J. Clin. Oncol. https://doi.org/10.1200/JCO.21.01308 (2022).
Chen, Y., Gao, M., Huang, Z., Yu, J. & Meng, X. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. J. Hematol. Oncol. 13, 105 (2020).
Min, Y., Li, X., Chen, H., Xu, Y. & Lan, G. Predicting outcomes of Lung Cancer using the modified glasgow prognostic score: A systematic review and meta-analysis. Pak J. Med. Sci. 40, 534–543 (2024).
Saal, J. et al. Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition. Lung Cancer. 189, 107505 (2024).
Yang, C., Ren, G. & Yang, Q. Prognostic value of preoperative modified Glasgow prognostic score in surgical non-small cell lung cancer: A meta-analysis. Front. Surg. 9, 1094973 (2022).
Saeed, R., McSorley, S., Cascales, A. & McMillan, D. C. The prognostic/ predictive value of the systematic inflammatory response in patients receiving immunotherapy for non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer. 25, 994 (2025).
Kishi, T. et al. Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. Int. J. Radiat. Oncol. Biol. Phys. 92, 619–626 (2015).
Chen, Z. et al. Modified Glasgow Prognostic Score is predictive of prognosis for non-small cell lung cancer patients treated with stereotactic body radiation therapy: a retrospective study. J. Radiat. Res. 62, 457–464 (2021).
Therneau, T. M. A Package for Survival Analysis in R. (2024).
Kassambara, A., Kosinski, M. & Biecek, P. Survminer: Drawing Survival Curves Using ‘Ggplot2’. (2021).
Gordon, M. & Lumley, T. Forestplot: Advanced Forest Plot Using ‘grid’ Graphics. (2024). https://doi.org/10.32614/CRAN.package.forestplot
Jin, J., Hu, K., Zhou, Y. & Li, W. Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis. PLoS ONE. 12, e0184412 (2017).
Lv, Y. et al. Modified Glasgow Prognostic Score at Recurrence Predicts Poor Survival in Resected Non-Small Cell Lung Cancer (NSCLC) Patients. Med. Sci. Monit. 23, 3780–3788 (2017).
Xie, Y., Li, H. & Hu, Y. Prognostic value of pretreatment modified Glasgow Prognostic Score in small cell lung cancer: A meta-analysis. Med. (Baltim). 102, e35962 (2023).
Patil, D. et al. Dynamic Evaluation of the Modified Glasgow Prognostic Scale in Patients with Resected, Localized Clear Cell Renal Cell Carcinoma. Urology https://doi.org/10.1016/j.urology.2020.03.024 (2020). doi:10.1016/j.urology.2020.03.024.
Jin, J., Hu, K., Zhou, Y. & Li, W. Prognostic value of the Glasgow prognostic score in lung cancer: evidence from 10 studies. Int. J. Biol. Markers. 33, 201–207 (2018).
Wu, J., Wang, H., Yang, R., Liu, D. & Li, W. Prognostic significance of the modified Glasgow Prognostic Score in NSCLC patients undergoing immune checkpoint inhibitor therapy: a meta-analysis. Front. Oncol. 14, 1449853 (2024).
Proctor, M. J. et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br. J. Cancer. 104, 726–734 (2011).
Ni, X. F. et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer. Asia Pac. J. Clin. Oncol. 14, 402–409 (2018).
Simmons, C. P. et al. Prognosis in advanced lung cancer–A prospective study examining key clinicopathological factors. Lung Cancer. 88, 304–309 (2015).
Miyazaki, T. et al. Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small-cell lung cancer in elderly patients. Surg. Today. 47, 836–843 (2017).
Takamori, S. et al. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer. 152, 27–33 (2021).
Tanaka, T. et al. Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies. Respiratory Invest. 61, 74–81 (2023).
Chang, J. Y. et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 402, 871–881 (2023).
Pircher, A. et al. 117O Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I/II non-small cell lung cancer (NSCLC): The randomized, double-blind, phase III KEYNOTE-867 study. Immuno-Oncology Technology 24, 100746 (2024).
Acknowledgements
The authors sincerely thank the medical staff at Shizuoka General Hospital for their dedicated support and care of the patients included in this study. The authors also acknowledge the Shizuoka Prefectural Hospital Organization Medical Research Promotion Project and the University of Yamanashi Publication Support Program for their institutional support.
Funding
Shizuoka Prefectural Hospital Organization Medical Research Promotion Project. University of Yamanashi Publication Support Program.
Author information
Authors and Affiliations
Contributions
Z.C. contributed to conceptualization, data curation, formal analysis, funding acquisition, resources, software, and writing of the original draft as well as review and editing. K.K. and M.O. contributed to data curation, resources, and writing – review and editing. M.E. contributed to investigation. K.Mi. contributed to methodology, resources, and writing – review and editing. M.Ma. contributed to resources. T.A. contributed to resources and writing – review and editing. K.Ma. contributed to resources and validation. T.K. contributed to resources. H.O. provided supervision and critical review and editing.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Chen, Z., Kuriyama, K., Oguri, M. et al. A prospective study on the predictive value of the modified Glasgow prognostic score in non-small cell lung cancer treated with radiation therapy. Sci Rep (2026). https://doi.org/10.1038/s41598-026-45248-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-45248-z
